Skip NavigationSkip to Content
Return Return to Search Results

Diazeniumdiolated carbamates: A novel class of nitric oxide donors

  1. Author:
    Nandurdikar, R. S.
    Maciag, A. E.
    Cao, Z.
    Keefer, L. K.
    Saavedra, J. E.

  2. Author Address

    [Nandurdikar, Rahul S.; Keefer, Larry K.] NCI, Drug Design Sect, Biol Chem Lab, Frederick, MD 21702 USA. [Maciag, Anna E.; Cao, Zhao; Saavedra, Joseph E.] NCI, Basic Sci Program, SAIC Frederick Inc, Frederick, MD 21702 USA.;Nandurdikar, RS (reprint author), NCI, Drug Design Sect, Biol Chem Lab, Frederick, MD 21702 USA;nandurdikarr@mail.nih.gov saavedjo@mail.nih.gov
    1. Year: 2012
    2. Date: Mar
  2. Journal: Bioorganic & Medicinal Chemistry
    1. 20
    2. 6
    3. Pages: 2025-2029
  4. Type of Article: Article
  5. ISSN: 0968-0896
  1. Abstract:

    We report an indirect method for synthesis of previously inaccessible diazeniumdiolated carbamates. Synthesis involves use of previously reported triisopropylsilyloxymethylated isopropylamine diazeniumdiolate (TOM-ylated IPA/NO). These novel diazeniumdiolated carbamate prodrugs upon activation release nitric oxide (NO) similar to their secondary amine counterparts. They are also efficient sources of intracellular NO. These prodrugs may have potential applications as therapeutic NO-donors. (C) 2012 Elsevier Ltd. All rights

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.bmc.2012.01.046
  3. View record in Web of Science®
  4. WOS: 000301201100023

Library Notes

  1. Fiscal Year: FY2011-2012
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel